MicroPort Endovascular MedTech Ltd (688016) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MicroPort Endovascular MedTech Ltd (688016) has a cash flow conversion efficiency ratio of 0.012x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥46.79 Million ≈ $6.85 Million USD) by net assets (CN¥3.98 Billion ≈ $582.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
MicroPort Endovascular MedTech Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how MicroPort Endovascular MedTech Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 688016 current and long-term liabilities for a breakdown of total debt and financial obligations.
MicroPort Endovascular MedTech Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MicroPort Endovascular MedTech Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DANAOS CORP. DL -01
F:DVW1
|
0.047x |
|
Pharvaris BV
NASDAQ:PHVS
|
-0.098x |
|
Beijing Yuanliu Hongyuan Electronic Technology Co Ltd
SHG:603267
|
-0.031x |
|
Mednax Inc
NYSE:MD
|
0.154x |
|
Capricor Therapeutics Inc
NASDAQ:CAPR
|
-0.077x |
|
TPV Technology Co Ltd
SHE:000727
|
-0.186x |
|
Beach Energy Ltd
AU:BPT
|
0.140x |
|
Poly Medicure Limited
NSE:POLYMED
|
0.031x |
Annual Cash Flow Conversion Efficiency for MicroPort Endovascular MedTech Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of MicroPort Endovascular MedTech Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see 688016 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥8.62 Billion ≈ $1.26 Billion |
CN¥573.06 Million ≈ $83.86 Million |
0.066x | -32.01% |
| 2024-12-31 | CN¥3.82 Billion ≈ $559.35 Million |
CN¥373.60 Million ≈ $54.67 Million |
0.098x | -33.89% |
| 2023-12-31 | CN¥3.86 Billion ≈ $565.36 Million |
CN¥571.22 Million ≈ $83.59 Million |
0.148x | -22.81% |
| 2022-12-31 | CN¥1.74 Billion ≈ $255.00 Million |
CN¥333.76 Million ≈ $48.84 Million |
0.192x | -2.91% |
| 2021-12-31 | CN¥1.52 Billion ≈ $222.73 Million |
CN¥300.25 Million ≈ $43.94 Million |
0.197x | +11.95% |
| 2020-12-31 | CN¥1.23 Billion ≈ $180.57 Million |
CN¥217.44 Million ≈ $31.82 Million |
0.176x | +31.17% |
| 2019-12-31 | CN¥1.07 Billion ≈ $155.98 Million |
CN¥143.20 Million ≈ $20.96 Million |
0.134x | -72.82% |
| 2018-12-31 | CN¥216.16 Million ≈ $31.63 Million |
CN¥106.85 Million ≈ $15.64 Million |
0.494x | +34.01% |
| 2017-12-31 | CN¥188.02 Million ≈ $27.51 Million |
CN¥69.36 Million ≈ $10.15 Million |
0.369x | +51.03% |
| 2016-12-31 | CN¥123.38 Million ≈ $18.05 Million |
CN¥30.13 Million ≈ $4.41 Million |
0.244x | -- |
About MicroPort Endovascular MedTech Ltd
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, and sale of aortic and peripheral vascular medical devices in China and internationally. The company offers branched aortic, thoracic, and bifurcated stent graft system; abdominal aortic stent graft and delivery system; and other stent graft system in surgical operation; as well as accessorie… Read more